161 related articles for article (PubMed ID: 18759699)
1. Targeting the endothelin system: novel therapeutic options in gynecological, urological and breast cancers.
Smollich M; Wülfing P
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1481-93. PubMed ID: 18759699
[TBL] [Abstract][Full Text] [Related]
2. The endothelin axis: a novel target for pharmacotherapy of female malignancies.
Smollich M; Wülfing P
Curr Vasc Pharmacol; 2007 Jul; 5(3):239-48. PubMed ID: 17627567
[TBL] [Abstract][Full Text] [Related]
3. Selective ETAR antagonist atrasentan inhibits hypoxia-induced breast cancer cell invasion.
Smollich M; Götte M; Kersting C; Fischgräbe J; Kiesel L; Wülfing P
Breast Cancer Res Treat; 2008 Mar; 108(2):175-82. PubMed ID: 17468950
[TBL] [Abstract][Full Text] [Related]
4. Small interfering RNA molecules targeting endothelin-converting enzyme-1 inhibit endothelin-1 synthesis and the invasive phenotype of ovarian carcinoma cells.
Rayhman O; Klipper E; Muller L; Davidson B; Reich R; Meidan R
Cancer Res; 2008 Nov; 68(22):9265-73. PubMed ID: 19010899
[TBL] [Abstract][Full Text] [Related]
5. The effect of castration on endothelins, their receptors and endothelin converting enzyme in rat prostate.
Takahashi W; Afiatpour P; Jr Foster HE; Ikeda K; Wada Y; Weiss RM; Latifpour J
Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug; 366(2):166-76. PubMed ID: 12122504
[TBL] [Abstract][Full Text] [Related]
6. Characterization of endothelin-converting enzyme activities in ARPE-19 cells, a human retinal pigmented epithelial cell line.
Dibas A; Prasanna G; Yorio T
J Ocul Pharmacol Ther; 2005 Jun; 21(3):196-204. PubMed ID: 15969636
[TBL] [Abstract][Full Text] [Related]
7. Modulation of human colon tumor-stromal interactions by the endothelin system.
Egidy G; Juillerat-Jeanneret L; Jeannin JF; Korth P; Bosman FT; Pinet F
Am J Pathol; 2000 Dec; 157(6):1863-74. PubMed ID: 11106559
[TBL] [Abstract][Full Text] [Related]
8. Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12.
Maguire JJ; Davenport AP
Br J Pharmacol; 2014 Dec; 171(24):5555-72. PubMed ID: 25131455
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic potential of endothelin-1 receptor antagonists and endothelin-converting enzyme inhibitors on the cardiovascular system.
Doggrell SA
Expert Opin Investig Drugs; 2002 Nov; 11(11):1537-52. PubMed ID: 12437501
[TBL] [Abstract][Full Text] [Related]
10. Prostaglandin F2alpha (PGF2alpha) independent and dependent regulation of the bovine luteal endothelin system.
Choudhary E; Costine BA; Wilson ME; Inskeep EK; Flores JA
Domest Anim Endocrinol; 2004 Jul; 27(1):63-79. PubMed ID: 15158535
[TBL] [Abstract][Full Text] [Related]
11. Endothelin system in oral squamous carcinoma cells: specific siRNA targeting of ECE-1 blocks cell proliferation.
Awano S; Dawson LA; Hunter AR; Turner AJ; Usmani BA
Int J Cancer; 2006 Apr; 118(7):1645-52. PubMed ID: 16217751
[TBL] [Abstract][Full Text] [Related]
12. On the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancer.
Smollich M; Götte M; Yip GW; Yong ES; Kersting C; Fischgräbe J; Radke I; Kiesel L; Wülfing P
Breast Cancer Res Treat; 2007 Dec; 106(3):361-9. PubMed ID: 17295044
[TBL] [Abstract][Full Text] [Related]
13. Vasoconstrictor activity of novel endothelin peptide, ET-1(1 - 31), in human mammary and coronary arteries in vitro.
Maguire JJ; Kuc RE; Davenport AP
Br J Pharmacol; 2001 Nov; 134(6):1360-6. PubMed ID: 11704658
[TBL] [Abstract][Full Text] [Related]
14. Of mice and men: advances in endothelin research and first antagonist gains FDA approval.
Davenport AP; Maguire JJ
Trends Pharmacol Sci; 2002 Apr; 23(4):155-7. PubMed ID: 11931980
[No Abstract] [Full Text] [Related]
15. Role of the astrocytic ET(B) receptor in the regulation of extracellular endothelin-1 during hypoxia.
Hasselblatt M; Lewczuk P; Löffler BM; Kamrowski-Kruck H; von Ahsen N; Sirén AL; Ehrenreich H
Glia; 2001 Apr; 34(1):18-26. PubMed ID: 11284016
[TBL] [Abstract][Full Text] [Related]
16. [Endothelin and kidney disease].
Nakayama Y; Tomita K
Nihon Rinsho; 2004 Sep; 62 Suppl 9():655-60. PubMed ID: 15506468
[No Abstract] [Full Text] [Related]
17. Cardiovascular effects of centrally applied endothelin-1 1-31 and its relationship to endothelin-1 1-21 in rats.
Lu Y; Wang LG; Liao Z; Tang CS; Wang WZ; Yuan WJ
Auton Neurosci; 2007 May; 133(2):146-52. PubMed ID: 17196890
[TBL] [Abstract][Full Text] [Related]
18. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?
Kirkby NS; Hadoke PW; Bagnall AJ; Webb DJ
Br J Pharmacol; 2008 Mar; 153(6):1105-19. PubMed ID: 17965745
[TBL] [Abstract][Full Text] [Related]
19. The endothelin-1 pathway and the development of cardiovascular defects in the haemodynamically challenged chicken embryo.
Groenendijk BC; Stekelenburg-de Vos S; Vennemann P; Wladimiroff JW; Nieuwstadt FT; Lindken R; Westerweel J; Hierck BP; Ursem NT; Poelmann RE
J Vasc Res; 2008; 45(1):54-68. PubMed ID: 17901707
[TBL] [Abstract][Full Text] [Related]
20. Endothelin-converting enzyme inhibitors for the treatment of subarachnoid hemorrhage-induced vasospasm.
Lin CL; Winardi W; Jeng AY; Kwan AL
Neurol Res; 2006 Oct; 28(7):721-9. PubMed ID: 17164035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
